This article was originally published in The Tan Sheet
Botanical-drug interaction grants to receive $4.3 mil. in FY 2001 funding, the NIH center announces in a request for applications released Aug. 7. NCCAM plans to support 10 Exploratory/Developmental Research (R21) grants and five investigator-initiated (R01) awards. Mechanistic, case control and Phase I and II trials will be considered. Letters of intent are due Nov. 10 and applications must be submitted by Jan. 12, 2001; the anticipated award date is August 2001. NCCAM's advisory council reviewed and endorsed the program concept in May (1"The Tan Sheet" May 15, p. 15)
You may also be interested in...
A project concept calling for the study of botanical/ drug interactions in animal models through Phase I/II clinical studies was approved by the National Center for Complementary & Alternative Medicine's advisory council at a May 8 meeting in Rockville, Md.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning